CurePSP, a Maryland-based non-profit advocacy organization, has launched the Patient Engagement Program (PEP) to increase clinical trial recruitment and and ultimately speed the development of treatments for neurodegenerative disorders. CurePSP is focused on “prime of life” neurodegenerative diseases, including progressive supranuclear palsy (PSP), a fatal, frontotemporal brain disorder. The key components of PEP, which will initially focus on PSP clinical trials, will be to link patients with clinical trials ongoing at companies and research institutions, and to work with clinicians and allied heath professionals on clinical trial recruitment strategies. Agreements have already been made between the non-profit and the pharmaceutical companies Bristol-Myers Squibb (BMS) and AbbVie. Both AbbVie and BMS have recently initiated Phase I clinical trials in PSP, testing C2N-8E12 and BMS-986168, respectively.
Click here to read more.